Thomas Kotarakos
Vermögen: - $ am 31.05.2026
Vermögen: - $ am 31.05.2026
Thomas Kotarakos is Chief Financial Officer at Parabilis Medicines, Inc. starting in 2026.
Formerly, Mr. Kotarakos was Controller at Seres Therapeutics, Inc. from 2014 to 2018 and Senior VP-Finance & Business Operations at Codiak BioSciences, Inc. from 2018 to 2021.
Education includes undergraduate and graduate degrees from Bentley University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 10.06.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| PARABILIS MEDICINES, INC. | Finanzdirektor/CFO | 10.12.2021 |
| Unternehmen | Position | Ende |
|---|---|---|
| CODIAK BIOSCIENCES | Corporate Officer/Principal | 01.12.2021 |
| SERES THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 01.10.2018 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
Bentley University
Bentley University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Seres Therapeutics, Inc.
Seres Therapeutics, Inc. BiotechnologyHealth Technology Develops novel treatments for diseases related to the human microbiome | Health Technology |
Parabilis Medicines
Parabilis Medicines Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops medicines for cancers and tumors | Health Technology |
Codiak BioSciences, Inc.
Codiak BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops exosome based therapeutics | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen